Scilex Holding Company Announces The Completion Of SP-103 5.4%, Triple Strength Formulation Of Ztlido, Phase 2 Trial Which Achieved Its Objectives To Evaluate The Safety And Efficacy Of SP-103 In Subjects With Moderate To Severe Acute Lower Back Pain
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding Company has completed its Phase 2 trial for SP-103, a drug candidate for the treatment of acute lower back pain. The trial, which enrolled 75 patients across 10 U.S. sites, achieved its objectives of evaluating the safety and efficacy of SP-103. The drug received Fast Track status from the FDA in September 2022 and has the potential to be a leading treatment for lower back pain, with a potential global market opportunity of approximately $10.0 billion by 2026.
September 14, 2023 | 1:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scilex's successful completion of the Phase 2 trial for SP-103 could potentially position the company as a leading player in the treatment of acute lower back pain, a market expected to be worth $10 billion by 2026.
The successful completion of the Phase 2 trial for SP-103 indicates that the drug is safe and effective for treating acute lower back pain. Given the Fast Track status granted by the FDA, the drug could potentially reach the market faster. This could significantly boost Scilex's revenues, especially considering the large market opportunity for such treatments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100